PNPLA3 and hepatocellular carcinoma: Importantly, the prevalence of ACLD, dACLD and CSPH was significantly higher in patients with the PNPLA3 G-allele (ACLD: 30.0% vs. 19.1%, p < 0.001; dACLD: 7.7% vs. 4.3%, p = 0.012 b; CSPH: 18.0% vs. 11.4%, p = 0.001), and there was a numeric trend towards more frequent HCC (2.1% vs. 0.8%, p = 0.063, Supplementary Table S3).